2001
Evidence of rodent-associated Bartonella and Rickettsia infections among intravenous drug users from Central and East Harlem, New York City.
Comer J, Diaz T, Vlahov D, Monterroso E, Childs J. Evidence of rodent-associated Bartonella and Rickettsia infections among intravenous drug users from Central and East Harlem, New York City. American Journal Of Tropical Medicine And Hygiene 2001, 65: 855-60. PMID: 11791987, DOI: 10.4269/ajtmh.2001.65.855.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsAntibodies, BacterialBartonellaBartonella InfectionsCohort StudiesCross ReactionsFemaleFluorescent Antibody Technique, IndirectHIV SeropositivityHumansMaleNew York CityPrevalenceRatsRickettsiaRickettsia InfectionsSubstance Abuse, IntravenousSurveys and QuestionnairesUrban HealthConceptsInjection drug usersDrug usersGroup rickettsiaeSerum samplesIntravenous drug usersCross-adsorption studiesEast HarlemR. akari infectionPrimary etiologic agentTyphus group rickettsiaeFever group rickettsiaeIDU populationHigh prevalenceEtiologic agentNew York CityRickettsia akariBartonella henselaeAntigenTesting panelsRickettsia typhiB. henselaeBartonella quintanaR. rickettsiiRickettsia infectionR. akariNeedle-exchange participation, effectiveness, and policy: Syringe relay, gender, and the paradox of public health
Valente T, Foreman R, Junge B, Vlahov D. Needle-exchange participation, effectiveness, and policy: Syringe relay, gender, and the paradox of public health. Journal Of Urban Health 2001, 78: 340-349. PMID: 11419584, PMCID: PMC3456352, DOI: 10.1093/jurban/78.2.340.Peer-Reviewed Original ResearchMeSH KeywordsAdultBaltimoreCommerceCommunity Health PlanningCounselingFemaleHealth BehaviorHealth EducationHIV InfectionsHumansInterpersonal RelationsMaleMiddle AgedNeedle-Exchange ProgramsOrganizational ObjectivesProgram EvaluationSocial SupportSubstance Abuse, IntravenousSurveys and QuestionnairesSyringesUrban HealthConceptsNeedle exchange programsNEP useIntravenous drug usersBaltimore Needle Exchange ProgramPublic health goalsHIV seroconversionHIV protectionDrug usersHealth goalsVirus transmission rateHigh usersDuration of contactPublic healthEducation effortsCirculation timeMost studiesRelay activityExclusive useParticipantsSeroconversionHIVVisitsWomen
1999
Serologic evidence of rickettsialpox (Rickettsia akari) infection among intravenous drug users in inner-city Baltimore, Maryland.
Comer J, Tzianabos T, Flynn C, Vlahov D, Childs J. Serologic evidence of rickettsialpox (Rickettsia akari) infection among intravenous drug users in inner-city Baltimore, Maryland. American Journal Of Tropical Medicine And Hygiene 1999, 60: 894-8. PMID: 10403316, DOI: 10.4269/ajtmh.1999.60.894.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BacterialBaltimoreCohort StudiesCross ReactionsDrinkingFemaleFluorescent Antibody Technique, IndirectHIV SeropositivityHumansIll-Housed PersonsMaleRickettsiaRickettsia InfectionsRickettsia rickettsiiRisk FactorsSeroepidemiologic StudiesSubstance Abuse, IntravenousUrban PopulationConceptsIntravenous drug usersInner-city BaltimoreDrug usersSerologic evidenceSerum samplesAcute febrile illnessR. rickettsiiR. akariHuman immunodeficiency virusSignificant risk factorsSignificant inverse associationCross-adsorption studiesPresence of antibodiesSingle serum sampleR. akari infectionFrequency of injectionsFever group rickettsiaeFebrile illnessUndetermined etiologyImmunodeficiency virusInverse associationRisk factorsGroup-specific antibodiesDrug useHigh titersComparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure
Kimura M, Converse P, Astemborski J, Rothel J, Vlahov D, Comstock G, Graham N, Chaisson R, Bishai W. Comparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure. The Journal Of Infectious Diseases 1999, 179: 1297-1300. PMID: 10191241, DOI: 10.1086/314707.Peer-Reviewed Original ResearchConceptsTuberculin skin testIFN-gamma releaseTuberculosis infectionWhole-Blood Interferon-γ Release AssayStandard tuberculin skin testInterferon-γ release assaysPercent agreementCulture-confirmed tuberculosisHIV-seropositive subjectsTuberculin skin testingHuman immunodeficiency virusInterferon-gamma releaseIntravenous drug usersSingle blood drawSeronegative patientsTuberculosis exposureSkin testingUninfected personsImmunodeficiency virusSkin testBlood drawUrban BaltimoreDrug usersRelease assaysFurther evaluation
1997
Comparison of a Tuberculin Interferon-γ Assay with the Tuberculin Skin Test in High-Risk Adults: Effect of Human Immunodeficiency Virus Infection
Converse P, Jones S, Astemborski J, Vlahov D, Graham N. Comparison of a Tuberculin Interferon-γ Assay with the Tuberculin Skin Test in High-Risk Adults: Effect of Human Immunodeficiency Virus Infection. The Journal Of Infectious Diseases 1997, 176: 144-150. PMID: 9207360, DOI: 10.1086/514016.Peer-Reviewed Original ResearchConceptsTuberculin skin testHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionSkin testVirus infectionIFN-gammaNegative tuberculin skin testPositive tuberculin skin testInterferon-γ AssayTST induration diameterWhole bloodHigh-risk adultsIntravenous drug usersMycobacterium tuberculosis exposureWhole blood IFN-gammaIFN-gamma responsesCutaneous anergyMitogen controlSeronegative subjectsTuberculosis exposureHIV infectionTuberculin reactivityWhole heparinized bloodInduration diameterDrug users
1996
Antibodies to Bartonella Species in Inner-city Intravenous Drug Users in Baltimore, Md
Comer J, Flynn C, Regnery R, Vlahov D, Childs J. Antibodies to Bartonella Species in Inner-city Intravenous Drug Users in Baltimore, Md. JAMA Internal Medicine 1996, 156: 2491-2495. PMID: 8944742, DOI: 10.1001/archinte.1996.00440200111014.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus statusB quintanaRisk factorsDrug usersB henselaeDrug useVirus statusHuman immunodeficiency virus-seropositive individualsHuman immunodeficiency virus (HIV) infectionSerum samplesImmunodeficiency virus infectionAvailable serum samplesSignificant risk factorsBehavioral risk factorsPossible risk factorsSignificant inverse associationIndirect immunofluorescent antibodyFrequency of injectionsUrban transmission cyclesBartonella speciesBartonella organismsMode of transmissionCurrent natural historyImmunodeficiency syndromeEvidence for HIV Type 1 Strains of U.S. Intravenous Drug Users as Founders of AIDS Epidemic among Intravenous Drug Users in Northern Europe
Lukashov V, Kuiken C, Vlahov D, Coutinho R, Goudsmit J. Evidence for HIV Type 1 Strains of U.S. Intravenous Drug Users as Founders of AIDS Epidemic among Intravenous Drug Users in Northern Europe. AIDS Research And Human Retroviruses 1996, 12: 1179-1183. PMID: 8844022, DOI: 10.1089/aid.1996.12.1179.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHomosexual menDrug usersV3 sequencesEuropean intravenous drug usersHIV Type 1 StrainsAIDS epidemicHIV-1 epidemicGp120 V3 loopSignature pattern analysisType 1 strainsRisk groupsV3 loopEpidemiological linkMenEpidemicVirusUnited StatesSuggestive evidencePresent suggestive evidenceHigh levelsNucleotide substitutionsEuropean origin
1994
Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users
Aylward R, Vlahov D, Muñoz A, Rapiti E. Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users. AIDS 1994, 8: 1129-1134. PMID: 7986411, DOI: 10.1097/00002030-199408000-00015.Peer-Reviewed Original ResearchConceptsIntravenous drug usersClinical stage 1Proportional hazards modelStaging systemProduct limit estimatesWorld Health OrganizationALIVE studyHIV diseaseHazards modelPopulation of IVDUWorld Health Organization (WHO) staging systemDrug usersCox proportional hazards modelStage 1WHO staging systemTime of progressionStage 2Index visitHIV seropositivityHIV-seropositivePrognostic utilityClinical stageClinical criteriaOriginal cohortClinical signsThe trading of sex for drugs or money and HIV seropositivity among female intravenous drug users.
Astemborski J, Vlahov D, Warren D, Solomon L, Nelson K. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. American Journal Of Public Health 1994, 84: 382-7. PMID: 8129052, PMCID: PMC1614821, DOI: 10.2105/ajph.84.3.382.Peer-Reviewed Original ResearchConceptsFemale intravenous drug usersIntravenous drug usersHIV seropositivityHIV infectionDrug usersHuman immunodeficiency virus (HIV) seroprevalenceIntravenous drug useDrug-using womenTrading of sexCohort studyVirus seroprevalenceDrug useCocaine useIntensive interventionLogistic regressionSeropositivityNumber of partnersMultivariate modelDrugsWomenSexInfectionGroupHigh levelsSeroprevalenceComparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users
Schültz C, Vlahov D, Anthony J, Graham N. Comparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users. Journal Of Clinical Epidemiology 1994, 47: 191-195. PMID: 8113828, DOI: 10.1016/0895-4356(94)90024-8.Peer-Reviewed Original Research
1993
Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection
Semba R, Graham N, Caiaffa W, Margolick J, Clement L, Vlahov D. Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection. JAMA Internal Medicine 1993, 153: 2149-2154. PMID: 8379807, DOI: 10.1001/archinte.1993.00410180103012.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionHIV-1-seropositive individualsVirus type 1 infectionCD4 T cellsHIV-1 infectionType 1 infectionPlasma vitaminT cellsHIV-1-seronegative individualsMean plasma vitaminLow CD4 levelsIntravenous drug usersHIV-seropositive participantsBlood cell countImportant risk factorNormal immune functionMumol/LCD4 levelsSeronegative individualsImmunologic statusSerologic markersClinical outcomesLiver diseaseSeropositive individualsIncreased MortalityComparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men
Palenicek J, Nelson K, Vlahov D, Galai N, Cohn S, Saah A. Comparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men. JAMA Internal Medicine 1993, 153: 1806-1812. PMID: 8101438, DOI: 10.1001/archinte.1993.00410150094009.Peer-Reviewed Original ResearchConceptsIntravenous drug usersCD4 cell levelsClinical symptomsDrug usersHomosexual menOral candidiasisHIV infectionPhysical examinationRisk groupsMale intravenous drug usersHuman immunodeficiency virus (HIV) diseaseRisk behavior interviewsCD4 cell countTotal lymphocyte countIntravenous drug useShortness of breathMost clinical symptomsHIV-1 infectionHuman immunodeficiency virusFrequency of symptomsIntermediate outcome measuresCell levelAbnormal hematocritHIV immunosuppressionNight sweatsDetection of Human Immunodeficiency Virus Type 1 Infection by Polymerase Chain Reaction in a Cohort of Seronegative Intravenous Drug Users
Farzadegan H, Vlahov D, Solomon L, Muñoz A, Astemborski J, Taylor E, Burnley A, Nelson K. Detection of Human Immunodeficiency Virus Type 1 Infection by Polymerase Chain Reaction in a Cohort of Seronegative Intravenous Drug Users. The Journal Of Infectious Diseases 1993, 168: 327-331. PMID: 8335969, DOI: 10.1093/infdis/168.2.327.Peer-Reviewed Original ResearchConceptsSeronegative intravenous drug usersIntravenous drug usersHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionPolymerase chain reactionDrug usersHIV-1 infectionHIV-1 antibodiesChain reactionLarge cohortBlood specimensProviral DNAInfectionCohortPCR analysisPersonsSerologyFollowVisitsAntibodiesMonthsDifferences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users
Solomon L, Astemborski J, Warren D, Muñoz A, Cohn S, Vlahov D, Nelson K. Differences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users. American Journal Of Epidemiology 1993, 137: 892-898. PMID: 8484380, DOI: 10.1093/oxfordjournals.aje.a116750.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus type 1 (HIV-1) seroconversionDrug usersSeronegative controlsRisk factorsFemale intravenous drug usersMale intravenous drug usersSex-specific risk factorsCurrent intravenous drug useHIV-seronegative controlsIntravenous drug useRisk of seroconversionRisk factor dataCase-control studyAge 18 yearsConditional logistic regression techniquesTime of interviewMore sex partnersSeroconversion statusSeroconversion visitHIV seroconversionHIV infectionStudy entrySexual transmissionSeroconversionSocially desirable responding and self‐reported HIV infection risk behaviors among intravenous drug users
LATKIN C, VLAHOV D, ANTHONY J. Socially desirable responding and self‐reported HIV infection risk behaviors among intravenous drug users. Addiction 1993, 88: 517-526. PMID: 8485429, DOI: 10.1111/j.1360-0443.1993.tb02058.x.Peer-Reviewed Original ResearchFrequency of left ventricular dysfunction and other echocardiographic abnormalities in human immunodeficiency virus seronegative intravenous drug users
Willoughby S, Vlahov D, Herskowitz A. Frequency of left ventricular dysfunction and other echocardiographic abnormalities in human immunodeficiency virus seronegative intravenous drug users. The American Journal Of Cardiology 1993, 71: 446-447. PMID: 8430637, DOI: 10.1016/0002-9149(93)90451-h.Peer-Reviewed Original ResearchConceptsIntravenous drug usersSeronegative intravenous drug usersIllicit drug useDrug usersDrug useLeft ventricularHIV-seronegative intravenous drug usersHuman immunodeficiency virus (HIV) infectionHIV-seropositive patientsNormal coronary arteriesImmunodeficiency virus infectionLeft ventricular dysfunctionLV ejection fractionGlobal left ventricularDevelopment of cardiomyopathyEchocardiographic abnormalitiesEchocardiographic findingsLV dysfunctionSeropositive patientsVentricular dysfunctionEjection fractionHIV infectionRetrospective reviewImmunodeficiency syndromeCoronary angiogramPotential Use of Mass Media to Reach Urban Intravenous Drug Users with AIDS Prevention Messages
Jason J, Solomon L, Celentano D, Vlahov D. Potential Use of Mass Media to Reach Urban Intravenous Drug Users with AIDS Prevention Messages. Substance Use & Misuse 1993, 28: 837-851. PMID: 8359944, DOI: 10.3109/10826089309039660.Peer-Reviewed Original ResearchConceptsAIDS prevention messagesMass mediaLocal radio stationsSafer sex messagesMedia useMedia executivesNew programIntravenous drug usersAIDS messagesMedia reachRadio stationsTelevisionLocal prevention programsPrevention messagesHours/weekMessagesDrug usersMediumAiringCohort studyAIDS informationPrevention programsPSAWeeksUsers
1992
Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity
Concha M, Graham N, Muñoz A, Vlahov D, Royal W, Updike M, Nance-Sproson T, Seines O, McArthur J. Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity. American Journal Of Epidemiology 1992, 136: 1338-1348. PMID: 1362630, DOI: 10.1093/oxfordjournals.aje.a116446.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBaltimoreBlack or African AmericanCD4-Positive T-LymphocytesChronic DiseaseCognition DisordersConfounding Factors, EpidemiologicEducational StatusEmploymentEvaluation Studies as TopicFemaleHIV SeropositivityHIV SeroprevalenceHIV-1HumansLeukocyte CountLinear ModelsMaleMass ScreeningNeuropsychological TestsPopulation SurveillancePredictive Value of TestsPrisonsPsychomotor PerformanceSubstance Abuse, IntravenousConceptsNeuropsychological test performanceHIV-1 seropositivityIntravenous drug usersTest performanceNeuropsychological performancePractice effectsHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersVirus type 1 infectionSubstance abuseSignificant practice effectsHIV-1 serostatusType 1 infectionIntravenous Experience (ALIVE) studyFrequency of drugChronic substance abuseNeuropsychological functioningCognitive performanceImmunodeficiency syndromeAsymptomatic stageHigh prevalenceOutcome measuresDrug useIntoxicated individualsMultivariate analysisT-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection-Reply
Margolick J, Muñoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, Nelson K. T-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection-Reply. JAMA 1992, 268: 2517-2517. DOI: 10.1001/jama.1992.03490180047020.Peer-Reviewed Original ResearchHIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects.
Selnes O, McArthur J, Royal W, Updike M, Nance-Sproson T, Concha M, Gordon B, Solomon L, Vlahov D. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology 1992, 42: 1924-30. PMID: 1407574, DOI: 10.1212/wnl.42.10.1924.Peer-Reviewed Original ResearchConceptsIntravenous drug usersIntravenous drug useDrug usersHIV infectionSerostatus groupsHIV-seropositive intravenous drug usersDrug useHIV-1 infectionHigh-risk groupRoute of acquisitionLongitudinal neuropsychological evaluationCross-sectional comparisonPreexisting deficitAsymptomatic subjectsLongitudinal followAdditional cognitive impairmentPresymptomatic stageNeurocognitive abnormalitiesCognitive impairmentNeuropsychological evaluationNeuropsychological deficitsSame cohortBisexual menInfectionSignificant differences